Aptevo Therapeutics (APVO) Free Cash Flow (2015 - 2026)

Aptevo Therapeutics has reported Free Cash Flow for 12 years, with the latest figure at -$8.0 million in Q1 2026.

• Quarterly Free Cash Flow fell 21.67% year-over-year to -$8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 million (up 93.1% YoY) and the FY2025 annual result came in at -$25.6 million, down 7.63% from the prior year.
• Free Cash Flow fell to -$8.0 million in Q1 2026 per APVO's latest filing, from -$5.2 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $18.7 million in Q3 2025 and troughed at -$8.0 million in Q1 2026.
• A 5-year average of -$3.8 million and a median of -$5.8 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow slumped 245.66% in 2024, then jumped 457.83% in 2025.
• Over 5 years, Free Cash Flow stood at -$5.9 million in 2022, then advanced by 12.06% to -$5.2 million in 2023, then declined by 10.26% to -$5.8 million in 2024, then increased by 8.94% to -$5.2 million in 2025, then plunged by 52.56% to -$8.0 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$8.0 million, -$5.2 million, and $18.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.